Literature DB >> 11286476

Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line.

P S Mackie1, J L Fisher, H Zhou, P F Choong.   

Abstract

Local growth of osteosarcoma involves destruction of host bone by proteolytic mechanisms and/or host osteoclast activation. Osteoclast formation and activity are regulated by osteoblast-derived factors such as the osteoclast differentiating factor, receptor activator of NF-kappaB ligand (RANKL) and the inhibitor osteoprotegerin (OPG). We have investigated the in vitro effects of bisphosphonates on a clonal rat osteosarcoma cell line. The aminobisphosphonate pamidronate was added to UMR 106-01 cell cultures (10(-8)M to 10(-4)M up to 5 days). The non-aminobisphosphonate clodronate was administered for the same time periods (10(-6)M to 10(-2)M). Cell proliferation, apoptosis and mRNA expression was assessed. Both agents inhibited cell proliferation in a time- and dose-dependent manner. ELISA analysis demonstrated an increase in DNA fragmentation although there was no significant dose-related difference between the doses studied. Bisphosphonate-treated cultures had a greater subpopulation of cells exhibiting morphological changes of apoptosis. Expression of mRNA for osteopontin and RANKL was down-regulated by both agents, while the expression of mRNA for alkaline phosphatase, pro-alpha1(I) collagen and OPG was not altered. Out in vitro work suggests the bisphosphonates not only have direct effects on osteosarcoma cell growth and apoptosis, but also, by altering the relative expression of osteoclast-regulating factors, they may inhibit the activity of osteoclasts and their recruitment. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286476      PMCID: PMC2363848          DOI: 10.1054/bjoc.2000.1679

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  49 in total

1.  Apoptosis. The role of the endonuclease.

Authors:  M J Arends; R G Morris; A H Wyllie
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

2.  Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

Authors:  M Sato; W Grasser; N Endo; R Akins; H Simmons; D D Thompson; E Golub; G A Rodan
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

3.  Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin.

Authors:  M H Helfrich; S A Nesbitt; E L Dorey; M A Horton
Journal:  J Bone Miner Res       Date:  1992-03       Impact factor: 6.741

Review 4.  Osteoclast inhibition for the treatment of bone metastases.

Authors:  R E Coleman; O P Purohit
Journal:  Cancer Treat Rev       Date:  1993-01       Impact factor: 12.111

5.  Osteopontin--a possible anchor of osteoclasts to bone.

Authors:  F P Reinholt; K Hultenby; A Oldberg; D Heinegård
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

6.  Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption.

Authors:  F P Ross; J Chappel; J I Alvarez; D Sander; W T Butler; M C Farach-Carson; K A Mintz; P G Robey; S L Teitelbaum; D A Cheresh
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

7.  Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.

Authors:  M Sahni; H L Guenther; H Fleisch; P Collin; T J Martin
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Attachment to extracellular matrix molecules by cells differing in the expression of osteoblastic traits.

Authors:  R J Majeska; M Port; T A Einhorn
Journal:  J Bone Miner Res       Date:  1993-03       Impact factor: 6.741

9.  Treatment of bone metastases from breast cancer and myeloma with pamidronate.

Authors:  D Thiébaud; S Leyvraz; V von Fliedner; L Perey; P Cornu; S Thiébaud; P Burckhardt
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

10.  Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone.

Authors:  A M Flanagan; T J Chambers
Journal:  Bone Miner       Date:  1989-04
View more
  34 in total

1.  Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.

Authors:  Gatien Moriceau; Benjamin Ory; Laura Mitrofan; Chiara Riganti; Frédéric Blanchard; Régis Brion; Céline Charrier; Séverine Battaglia; Paul Pilet; Marc G Denis; Leonard D Shultz; Jukka Mönkkönen; Françoise Rédini; Dominique Heymann
Journal:  Cancer Res       Date:  2010-10-22       Impact factor: 12.701

2.  Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

Authors:  K Kananen; L Volin; K Laitinen; T Ruutu; M J Välimäki
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

3.  Degeneration of Paget's disease into sarcoma: clinical and therapeutic influencing factors.

Authors:  Alessandro Zati; Teresa Wanda Bilotta
Journal:  Chir Organi Mov       Date:  2008-04-12

4.  Bisphosphonates hinder osteoblastic/osteoclastic differentiation in the maxillary sinus mucosa-derived stem cells.

Authors:  Jun Zhang; Jaesuh Park; Jung-Woo Lee; Yong-Dae Kwon; Eun-Cheol Kim
Journal:  Clin Oral Investig       Date:  2017-11-30       Impact factor: 3.573

5.  Osteoclast responses to lipopolysaccharide, parathyroid hormone and bisphosphonates in neonatal murine calvaria analyzed by laser scanning confocal microscopy.

Authors:  Keiko Suzuki; Sadaaki Takeyama; Takashi Kikuchi; Shoji Yamada; Jaro Sodek; Hisashi Shinoda
Journal:  J Histochem Cytochem       Date:  2005-08-08       Impact factor: 2.479

6.  Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma.

Authors:  Crispin R Dass; Anne P W Nadesapillai; Daniel Robin; Monique L Howard; Jane L Fisher; Hong Zhou; Peter F M Choong
Journal:  Clin Exp Metastasis       Date:  2006-04-29       Impact factor: 5.150

7.  Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study.

Authors:  Hyung Keun Kim; Ji Hyun Kim; Azlina Amir Abbas; Taek Rim Yoon
Journal:  Clin Orthop Relat Res       Date:  2008-07-30       Impact factor: 4.176

8.  The influence of bisphosphonates on human osteoblast migration and integrin aVb3/tenascin C gene expression in vitro.

Authors:  Felix P Koch; Annette Wunsch; Christina Merkel; Thomas Ziebart; Andreas Pabst; Sareh Said Yekta; Marco Blessmann; Ralf Smeets
Journal:  Head Face Med       Date:  2011-02-07       Impact factor: 2.151

9.  The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro.

Authors:  James P Farese; Jenna Ashton; Rowan Milner; Linda-Lee Ambrose; James Van Gilder
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Mar-Apr       Impact factor: 2.416

10.  Risedronate inhibits human osteosarcoma cell invasion.

Authors:  Zeng Feng Xin; Yang Kyung Kim; Sung Taek Jung
Journal:  J Exp Clin Cancer Res       Date:  2009-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.